SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T‐cell neoplasms
British Journal of Haematology · 2023
DOI: 10.1111/bjh.18694 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Antonio Lahera und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Universidad Autónoma de Madrid, Madrid, Spain. Hauptthemen laut MEDLINE: Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia-Lymphoma, Adult T-Cell. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Comunidad de Madrid, Fundación Científica Asociación Española Contra el Cáncer, Fundación Ramón Areces.
Abstract (Originalsprache)
Despite the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway being frequently altered in T‐ALL/LBL, no specific therapy has been approved for T‐ALL/LBL patients with constitutive signalling by JAK/STAT, so there is an urgent need to identify pathway members that may be potential therapeutic targets. In the present study, we searched for JAK/STAT pathway members potentially modulated through aberrant methylation and identified SOCS3 hypermethylation as a recurrent event in T‐ALL/LBL. Additionally, we explored the implications of SOCS3 deregulation in T‐ALL/LBL and demonstrated that SOCS3 counteracts the constitutive activation of the JAK/STAT pathway through different molecular mechanisms. Therefore, SOCS3 emerges as a potential therapeutic target in T‐ALL/LBL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, Universidad Autónoma de Madrid, Madrid, Spain.
- Department of Genome dynamics and function, Centro de Biología Molecular Severo Ochoa (CBMSO), Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.
- Area of Genetics and Genomics, IIS Fundación Jiménez Díaz, Madrid, Spain.
- Institute for Molecular Biology-IUBM (Universidad Autónoma de Madrid), Madrid, Spain.
- Department of Molecular Biology, Universidad Autónoma de Madrid, Madrid, Spain.
- Laboratory for Biological Mass Spectrometry, Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK.
ORCID-Profile: Antonio Lahera, Pilar López-Nieva, José L Marín-Rubio, Pablo Fernández-Navarro, Agustín F Fernández, Laura Vela-Martín, Isabel Sastre, Sara Ruiz-García, José L López-Lorenzo, Javier Cornago, Javier Santos, José Fernández-Piqueras, María Villa-Morales
Förderung
- Comunidad de Madrid
- Fundación Científica Asociación Española Contra el Cáncer
- Fundación Ramón Areces
- Instituto de Investigación Sanitaria Fundación Jiménez Díaz
- Ministerio de Ciencia, Innovación y Universidades
- Ministerio de Economía y Competitividad
Zitieren
APA
Lahera, A., López-Nieva, P., Alarcón, H., Marín-Rubio, J. L., Cobos-Fernández, M. Á., Fernández-Navarro, P., Fernández, A. F., Vela-Martín, L., Sastre, I., Ruiz-García, S., Llamas, P., López-Lorenzo, J. L., Cornago, J., Santos, J., Fernández-Piqueras, J., & Villa-Morales, M. (2023). SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T‐cell neoplasms. British Journal of Haematology. https://doi.org/10.1111/bjh.18694
Vancouver
Lahera A, López-Nieva P, Alarcón H, Marín-Rubio JL, Cobos-Fernández MÁ, Fernández-Navarro P, et al. SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T‐cell neoplasms. British Journal of Haematology. 2023. doi:10.1111/bjh.18694
BibTeX
@article{Lahera2023,
author = {Lahera, Antonio and López-Nieva, Pilar and Alarcón, Hernán and Marín-Rubio, José L and Cobos-Fernández, María Á and Fernández-Navarro, Pablo and Fernández, Agustín F and Vela-Martín, Laura and Sastre, Isabel and Ruiz-García, Sara and Llamas, Pilar and López-Lorenzo, José L and Cornago, Javier and Santos, Javier and Fernández-Piqueras, José and Villa-Morales, María},
title = {SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T‐cell neoplasms},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.18694}
}
EUVIMED